2017-08-04T13:34:13-05:00 2016-12-31 WOLF & COMPANY PC 99 HIGH STREET 21ST FLOOR BOSTON MA 02110 990 2016-01-01 900133592 Addgene Inc % MICHAEL LOHNES ADDG 6172259000 75 Sidney Street Suite 550A Cambridge MA 02139 MICHAEL LOHNES director of finance 6172259000 2017-08-04 true Anthony T Carideo JR CPA P00171579 6174399700 2017-07-20 74.92.33.29 04102520172165000000 2017-08-04 P FC2C3B3E33F5728E88F8F1C970CCBE89E423E2A2 AB4632533840A799C2F045CE9F5D9B6D33CBA32F 2016 2021-01-29 14:40:06Z Joanne Kamens 75 Sidney Street 550A Cambridge MA 02139 10886480 false X www.addgene.org X 2004 MA see form 990, part iii, line 1 10 7 72 9 570 0 57500 9573301 10825972 -33336 3008 0 0 9539965 10886480 0 0 0 0 3776664 4807363 0 0 0 4747745 5563330 8524409 10370693 1015556 515787 10380279 10578873 1563038 1247281 8817241 9331592 ADDGENE, INC. PROVIDES RESEARCH SUPPORT SERVICE DEDICATED TO ARCHIVING AND DISTRIBUTING PLASMIDS THAT APPEAR IN PUBLISHED ARTICLES. BY LINKING PLASMIDS WITH PUBLICATIONS, SCIENTISTS ARE ALWAYS CONNECTED TO DATA GENERATED FROM THE MATERIALS THAT THEY ARE REQUESTING. THE COMPANY'S GOAL IS TO COMPILE A COMPREHENSIVE LIBRARY OF PLASMIDS TO FACILITATE RESEARCH AND DISCOVERY. false false 7750926 10825972 the storage and distribution of dna-based reagents in support of scientific research. 7750926 true true false false false false false false false false true false false false false true true false false true true false false false false false false false false true false false false false false false false true false false false false false false false false false true 13 0 true 72 true true true false false false false false false false false false false false X 10 7 true false false false false false false true true false false true true true true true true true true false MA X MICHAEL LOHNES 6172259000 75 SIDNEY STREET SUITE 550A Cambridge MA 02139 David E Brook director (term ended jan 2016) 1.0 0.0 X 0 0 0 Benjie Chen director 1.0 0.0 X 0 0 0 Constance Cepko director 1.0 0.0 X 0 0 0 David Root director 1.0 0.0 X 0 0 0 Judy Tsai Chuk director (term ended Jan 2016) 1.0 0.0 X 0 0 0 Joanne Kamens president/director 40.0 0.0 X X 186892 0 21040 Kenneth Fan treasurer/director 1.0 0.0 X X 0 0 0 Melina Fan Dir/Chief scientific officer 40.0 0.0 X X 183616 0 27683 Kristin Darby director 1.0 0.0 X 0 0 0 Joanna Brownstein director 1.0 0.0 X 0 0 0 Michael Koeris director 1.0 0.0 X 0 0 0 Darrell Kotton director (eff. May 2016) 1.0 0.0 X 0 0 0 John H Chu clerk 1.0 0.0 X 0 0 0 Michael Lohnes director of finance 40.0 0.0 X 117982 0 12318 Lianna Swanson senior director of biology 40.0 0.0 X 114204 0 22208 Pamela McA'Nulty Chief Architect 40.0 0.0 X 140376 0 20078 Morgan Wahl sr. sofware engineer 40.0 0.0 X 99390 0 17122 Andrew Baltus Dir of business development 40.0 0.0 X 106006 0 13496 Eric Perkins sr. scientific project leader 40.0 0.0 X 99521 0 6857 1047987 0 140802 6 false true false ups 955 massachusetts ave CAMBRIDGE MA 02139 shipping 1299893 LGC Limited QUEENS ROAD TEDDINGTON MIDDLESEX UK TW11 0LY consulting services 380391 Springbok llc 50 milk st 16th floor BOSTON MA 02109 IT CONTRACTOR 138199 ViGene Biosciences Inc 9430 Key West Ave Suite 105 TOCKVILLE MD 20850 plamid cloning svcs 163435 VWR International LLC po box 640169 PITSBURGH PA 15264 Lab Services 160204 6 57500 57500 PLASMID SALES 541700 10825972 10825402 570 10825972 3008 3008 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10886480 10825402 570 3008 0 0 0 0 488490 341943 146547 0 3298272 2299552 998720 0 710554 390100 320454 310047 217033 93014 0 15284 1528 13756 19506 19506 0 0 0 401816 266274 135542 127256 120892 6364 153333 70925 82408 255510 125730 129780 0 1433557 1001087 432470 100901 68693 32208 0 13850 6925 6925 0 0 229961 172471 57490 44062 44062 PRODUCT SHIPPING FEES 1447410 1447410 LAB EXPENSES 1086018 1086018 ORDER MERCHANT CARD FEES 113425 113425 BAD DEBT EXP 81933 81933 39508 20920 18588 10370693 7750926 2619767 0 0 7797668 7982998 540645 0 0 629529 730747 0 0 0 0 0 0 0 193133 91895 92279 1398738 515026 871571 883712 0 0 247813 0 0 0 0 0 556473 340689 10380279 10578873 1168893 870595 0 0 394145 376686 0 0 0 0 0 0 0 0 0 0 0 0 1563038 1247281 X 8817241 9331592 0 0 0 0 8817241 9331592 10380279 10578873 X 515787 2187 -3623 X false true X true X DANA-FARBER CANCER INSTITUTE boston MA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 106971 18667 88304 854066 336794 517272 437701 159565 278136 883712 0 0 X 10885044 2187 -3623 -1436 10886480 10886480 10370693 10370693 10370693 Schedule D, Part X, Line 2 - Uncertain Tax Position The Company is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3) and therefore has made no provision for federal or state income taxes. The Company follows accounting guidance regarding the recognition, measurement, presentation, and disclosure of uncertain tax positions in the financial statements. Tax positions taken or expected to be taken in the course of preparing the Companys tax returns, including the position that the Company qualifies as a tax exempt entity, are required to be evaluated to determine whether the tax positions are "more-likely-than-not" to be upheld under regulatory review. Tax positions not deemed to meet a more-likely-than-not threshold would be disclosed in the financial statements. There were no uncertain tax positions that require disclosure in the financial statements as of December 31, 2016 and 2015. The Company records interest and penalties, if any, as part of income tax expense. No interest or penalties were recorded in 2016 or 2015. The Companys income tax returns are subject to review and examination by federal and state taxing authorities. The Company is currently open to audit under the applicable statutes of limitations by the Internal Revenue Service and state taxing authorities for the years ended after December 31, 2012. Schedule D, Part XI, Line 2d: foreign currency translation (loss) (3,623) Europe (Including Iceland and Greenland) Program Services Maketing/Admin service 380391 380391 380391 false false false false false false X X X X X false false false false false false false false false Joanne Kamens president/director 179376 0 7000 0 516 0 2102 0 18938 0 207932 0 0 0 Melina Fan Dir/Chief scientific officer 176256 0 7000 0 360 0 5331 0 22352 0 211299 0 0 0 Pamela McA'Nulty Chief Architect 132923 0 7000 0 453 0 0 0 20078 0 160454 0 0 0 Compensation committee The independent board members act as the compensation committee and have in place a formal written process to evaluate and set the compensation of the CEO and other officers. CHU RING HAZEL JOHN CHU, ptr of law firm 8707 LEGAL FEES false Hamilton Brook Smith Reynolds David Brook, partner 4882 legal fees false 990, PART VI, SECTION A, LINE 2 - FAMILY RELATIONSHIP MELINA FAN AND KENNETH FAN ARE SIBLINGs. MELINA FAN AND BENJIE CHEN ARE SPOUSES. 990, PART VI, SECTION B, LINE 11 - REVIEW PROCESS OF FORM 990 FORM 990 WAS REVIEWED BY MANAGEMENT ALONG WITH THE AUDITED FINANCIAL STATEMENTS. A FULL COPY OF FORM 990 IS PROVIDED TO ALL BOARD MEMBERS FOR REVIEW PRIOR FILING TO THE IRS. 990, PART VI, SECTION B, LINE 12 - CONFLICT OF INTEREST POLICY ADDGENE, INC. HAS A CONFLICT OF INTEREST POLICY IN PLACE. ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE REQUIRED TO DISCLOSE ANNUALLY any INTERESTS THAT COULD GIVE RISE to CONFLICTS. INQUIRES ARE MADE DURING BOARD OF DIRECTOR MEETINGS. 990, PART VI, SECTION B, LINE 15 - PROCESS FOR DETERMINING COMPENSATION ADDGENE, INC.'S INDEPENDENT BOARD MEMBERS REVIEWED AND DETERMINED THE COMPENSATION OF ALL OFFICERS ANNUALLY. 990, PART VI, SECTION C, LINE 19 - ORGANIZATION DOCUMENTS ADDGENE, INC.'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS are AVAILABLE TO THE PUBLIC UPON REQUEST. 990, PART XI, LINE 9 - OTHER CHANGES IN NET ASSETS Foreign currency translation (loss) (3,623)